Hangzhou Alltest Biotech Co., Ltd.

XSSC:688606 Stock Report

Market Cap: CN¥4.9b

Hangzhou Alltest Biotech Past Earnings Performance

Past criteria checks 1/6

Hangzhou Alltest Biotech's earnings have been declining at an average annual rate of -20.2%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been declining at an average rate of 5% per year. Hangzhou Alltest Biotech's return on equity is 7.1%, and it has net margins of 34%.

Key information

-20.2%

Earnings growth rate

-24.4%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate-5.0%
Return on equity7.1%
Net Margin34.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hangzhou Alltest Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSSC:688606 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24813277139103
30 Jun 24763233142104
31 Mar 24718185140108
31 Dec 23755181147121
30 Sep 23938-74142138
30 Jun 231,053-47164173
31 Mar 231,526176212197
31 Dec 223,3891,185236207
30 Sep 223,8871,644234189
30 Jun 223,9611,742197157
31 Mar 223,6841,665138124
31 Dec 211,8737668795
30 Sep 211,5227848387
30 Jun 211,2846907469
31 Mar 211,3567977364
31 Dec 201,1366796355
31 Dec 19241783536
31 Dec 18184562031
31 Dec 17130341726
31 Dec 167615920

Quality Earnings: 688606 has a high level of non-cash earnings.

Growing Profit Margin: 688606 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688606's earnings have declined by 20.2% per year over the past 5 years.

Accelerating Growth: 688606 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 688606 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-8.8%).


Return on Equity

High ROE: 688606's Return on Equity (7.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 05:01
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hangzhou Alltest Biotech Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution